The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Path: Granulomatous lymphadenopathy
Publications
Sagawa T, Sato Y, Nagashima H, Takada K, Takahashi M, Hirakawa M, Hamaguchi K, Tamura F, Fujikawa K, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Frontiers in immunology 2023;14;1203621 — 2023 — 1203621
Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 08;13;1076-1082 — 2018 08 — 1076-1082
EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer.
Respiration; international review of thoracic diseases 2017;94;518-521 — 2017 — 518-521